Thematic photoMartin FalbisonerCC BY-SA 3.0Resized, encoded as WebP; displayed with responsive cropping under the original licenceSEC EDGAR published this disclosure on 2026-08-20. Read the original document for its full text and supporting detail.
Open the original document at SEC EDGAR ↗accession0001470831-26-000848
acquired disposedD
codeS
direct or indirectD
form4
is derivativefalse
issuer nameBridgeBio Pharma, Inc.
labelOpen market sale
Source record & verificationDates, provenance and technical details
Context
links are based on the recorded entity typeRecorded payloadStructured source data
Recorded payload
JSON payload as stored after parsing{
"accession": "0001470831-26-000848",
"acquired_disposed": "D",
"code": "S",
"direct_or_indirect": "D",
"form": "4",
"is_derivative": false,
"issuer_name": "BridgeBio Pharma, Inc.",
"label": "Open market sale",
"person_name": "Kumar Neil",
"price": 83.7732,
"role": "Director, Chief Executive Officer",
"security": "Common Stock",
"shares": 1199,
"shares_owned_after": 243327,
"source_path": "edgar/data/1743881/0001470831-26-000848.txt",
"ticker": "BBIO",
"transaction_date": "2026-08-18",
"value": 100444.0668
}Evidence-based analysis
facts, provenance and explicit model coverageDescriptive evidence from the stored source record; it is not advice, a forecast or a legal conclusion.